Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$71.22
+1.9%
$70.65
$61.24
$87.68
$220.91B0.385.21 million shs4.56 million shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$706.94
-0.1%
$602.45
$437.37
$714.30
$216.93B1.322.69 million shs1.58 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$777.73
-0.2%
$779.41
$677.09
$972.53
$737.25B0.413.88 million shs1.30 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.87
+2.6%
$23.51
$20.92
$31.54
$141.25B0.5746.13 million shs30.68 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$136.13
+1.0%
$134.23
$127.35
$159.64
$34.64B0.710.46 million shs13.53 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.04%-1.08%-4.04%-3.75%-10.40%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
+2.57%+9.46%+18.11%+29.17%+56.64%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.41%+1.19%+5.56%-3.03%-13.92%
Pfizer Inc. stock logo
PFE
Pfizer
+0.31%+0.96%+3.45%-1.04%-13.26%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+0.64%+1.99%+1.48%-5.96%-7.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.3024 of 5 stars
2.43.01.70.02.90.01.3
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.911 of 5 stars
2.23.04.23.02.23.33.8
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9816 of 5 stars
4.44.03.34.02.81.71.9
Pfizer Inc. stock logo
PFE
Pfizer
4.863 of 5 stars
2.33.04.24.32.81.73.1
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.83
Moderate Buy$85.0019.35% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.32
Hold$595.67-15.74% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6130.07% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1717.30% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.69
Moderate Buy$136.710.43% Upside

Current Analyst Ratings Breakdown

Latest GS, AZN, LLY, XLV, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$570.00 ➝ $592.00
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Moderate Sell
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.08$6.42 per share11.10$13.18 per share5.40
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$126.85B1.71$54.93 per share12.87$350.27 per share2.02
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.36$14.28 per share54.48$15.03 per share51.75
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.22$4.49 per share5.54$15.62 per share1.59
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4928.6114.241.2814.14%33.14%12.83%7/24/2025 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.28B$43.0916.4113.580.9411.86%13.76%0.87%7/16/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.3024.991.1322.67%85.51%15.74%8/7/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3818.008.210.8812.62%20.33%8.53%8/5/2025 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/A

Latest GS, AZN, LLY, XLV, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.11N/AN/AN/AN/AN/A
7/16/2025Q2 2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$9.82N/AN/AN/A$13.53 billionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/14/2025Q1 2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.57$14.12+$1.55$14.12$14.99 billion$15.06 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.89%N/A82.73%N/A
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.001.70%N/A27.85%13 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.92%N/A124.64%16 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.391.76%N/AN/AN/A

Latest GS, AZN, LLY, XLV, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
4/15/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$3.002.3%5/30/20255/30/20256/27/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.41
0.68
0.68
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
46,500306.84 million305.15 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.41 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A254.47 millionN/ANot Optionable

Recent News About These Companies

6 ETFs to Invest in June
Healthcare ETFs Slide as UnitedHealth Plunges
Young woman doctor holding a tablet pc — Photo
Top Analyst-Rated Healthcare Stocks to Watch Now (XLV)
...
SPDR Health Care Select Sector (XLV)
Health Care Sector In 2025: Buy Abbott Labs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$71.22 +1.34 (+1.92%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$706.94 -0.81 (-0.11%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$777.73 -1.80 (-0.23%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$24.86 +0.63 (+2.58%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$136.13 +1.34 (+0.99%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.